Northern, WI 06/20/2013 (usastockreport) – The share prices of Dynavax Technologies Corporation (NASDAQ:DVAX) had been traded in the price range of $1.01 and $1.14 on Wednesday. The company’s share price had had gradually increased by 8.65 percent, with a closing price of $1.13 per share. The share price of does not made a change in the 52 week low value $0.99 per share and 52 week high value $5.10 per share.
Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical stage bio pharmaceutical company discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HELPISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines.
The company has announced today that the 2013 Novartis Prize for Basic Immunology has been awarded to Dr. Robert L. Coffman, Chief Scientific Officer of Dynavax, and his former collaborator Dr. Tim R. Mossman for their groundbreaking research defining subsets of immune system T cells that advanced the understanding of infectious, auto immune and allergic disease.
The fundamental discoveries by both persons are the specific types of T- cells that helped either by cellular or humoral immunity revolutionized our understanding of how the immune systems works and led to major advances in designing therapies for infectious, inflammatory and allergic diseases and in vaccine design. The Novartis prizes for immunology are awarded every three years for breakthrough contributions to the fields of basic and clinical immunology as judged by an independent panel of experts.
The market capitalization value is about 206.67 million and institutional investors share’s percent is about 87. Dynavax has been having a trading volume as 6.76 million and the average volume as 3.49 million per day on Wednesday. The company presently holds 182.89 million shares outstanding in the market